Laparoscopic vs open total gastrectomy for advanced gastric cancer following neoadjuvant therapy: A propensity score matching analysis

Table 1 Patients and tumors’ clinical and pathological characteristics before and after propensity score matching

Variable	All patients		P value	Matched patients		P value
	LTG (n = 78)	OTG (n = 107)		LTG (n = 69)	OTG (n = 69)
Age (yr)	52.7 ± 16.1	56.0 ± 12.0	0.120	53.42 ± 13.4	53.9 ± 12.7	0.828
Gender n (%)
Male	61 (78.2)	78 (72.9)	0.409	53 (76.8)	52 (75.4)	0.842
Female	17 (21.8)	29 (27.1)		16 (23.2)	17 (24.6)
BMI (kg/m2)	22.6 ± 3.1	23.7 ± 3.7	0.028	22.6 ± 3.1	22.8 ± 3.3	0.750
ASA n (%)
1-2	74 (94.9)	99 (92.5)	0.522	65 (94.2)	64 (92.8)	1.000
3	4 (5.1)	8 (7.5)		4 (5.8)	5 (7.2)
The history of abdominalsurgery n (%)
Yes	10 (12.8)	19 (17.8)	0.362	8 (11.6)	13 (18.8)	0.236
No	68 (87.2)	88 (82.2)		61 (88.4)	56 (81.2)
Tumor location n (%)			0.775			0.698
Upper	30 (38.5)	35 (37.6)		28 (25.0)	22 (25.0)
Middle	25 (32.1)	42 (39.3)		23 (33.3)	26 (37.7)
Lower	9 (11.5)	12 (11.2)		7 (10.1)	10 (14.5)
More than two position or total	14 (17.9)	18 (16.8)		11 (15.9)	11 (15.9)
Clinical T stage n (%)			0.402			0.784
2	3 (3.8)	1 (0.9)		3 (4.3)	1 (1.4)
3	19 (24.4)	26 (24.3)		17 (24.6)	18 (26.1)
4	56 (71.8)	80 (74.8)		49 (71.0)	50 (72.5)
Clinical N stage n (%)			0.404			0.619
0	1 (1.3)	5 (4.7)		1 (1.4)	3 (4.3)
1-3	77 (98.7)	102 (95.3)		68 (98.6)	66 (95.7)
Clinical TNM stage n (%)			0.966			1.000
II	4 (5.1)	6 (5.6)		4 (5.8)	4 (5.8)
III	73 (93.6)	100 (93.5)		64 (92.8)	65 (94.2)
IVA	1 (1.3)	1 (0.9)		1 (1.4)	0 (0)
Tumor size (cm)	5.2 ± 3.1	6.0 ± 3.4	0.126	5.4 ± 3.3	5.4 ± 3.1	0.953
Nerve invasion n (%)			1.000			0.394
Yes	43 (55.1)	59 (55.1)		38 (55.1)	33 (47.8)
No	35 (44.9)	48 (44.9)		31 (44.9)	36 (52.2)
Lymph-vascular invasion n (%)			0.410			1.000
Yes	43 (55.1)	59 (55.1)		23 (33.3)	23 (33.3)
No	35 (44.9)	48 (44.9)		46 (66.7)	46 (66.7)
Differentiation n (%)			0.360			0.780
Well	4 (5.1)	3 (2.8)		1 (1.4)	2 (2.9)
Moderate	24 (30.8)	25 (23.4)		22 (31.9)	19 (27.5)
Poor	50 (64.1)	79 (73.8)		46 (66.7)	48 (69.6)
Pathological T stage n (%)			0.254			0.282
ypT0-1	8 (10.3)	8 (7.5)		6 (8.7)	7 (10.1)
ypT2	11 (14.1)	7 (6.5)		11 (15.9)	4 (5.8)
ypT3	23 (29.5)	31 (29.0)		17 (24.6)	21 (30.4)
ypT4a/4b	36 (46.2)	61 (57.0)		35 (50.7)	37 (53.6)
Pathological N stage n (%)			0.168			0.443
ypN0	26 (33.3)	26 (24.3)		23 (33.3)	18 (26.1)
ypN1	12 (15.4)	23 (21.5)		11 (15.9)	18 (26.1)
ypN2	16 (20.5)	14 (13.1)		14 (20.3)	11 (15.9)
ypN3	24 (30.8)	44 (41.1)		21 (30.4)	22 (31.9)
Distant metastasis n (%)			0.531			1.000
Yes	6 (7.7)	5 (4.7)		4 (5.8)	3 (4.3)
No	72 (92.3)	102 (95.3)		65 (94.2)	66 (95.7)
Pathological TNM stage n (%)			0.576			0.781
IIA	12 (15.4)	13 (12.1)		10 (14.5)	9 (13.0)
IIB	17 (55.1)	20 (64.5)		17 (24.6)	13 (18.8)
III	43 (55.1)	69 (64.5)		38 (55.1)	44 (63.8)
IV	6 (7.7)	5 (4.7)		4 (5.8)	3 (4.3)
Adjuvant chemotherapy n (%)			0.824			0.848
Yes	58 (74.4)	78 (72.9)		50 (72.5)	51 (73.9)
No	20 (25.6)	29 (27.1)		19 (27.5)	18 (26.1)

LTG: Laparoscopic total gastrectomy; OTG: Open total gastrectomy; BMI: Body mass index; ASA: Anesthesiologists physical status classification.